• EN/ES

    Orthopedics

    WebHealthNetwork : 2,378,479


  • Benefits & Savings

  • : Neurofibroma

Neurofibroma - 65 Studies Found

Terminated : Fludeoxyglucose F 18 Positron Emission Tomography and Magnetic Resonance Perfusion Imaging in Patients With Neurofibromatosis 1 and Plexiform Neurofibroma
:
  • Neurofibromatosis Type 1
  • Precancerous Condition

: 2003-05-06
:
  • Radiation: fludeoxyglucose F 18
  • Radiation:

Completed : Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas
:
  • Neurofibromatosis Type 1
  • Precancerous Condition

: 2003-02-05
: Drug: pirfenidone
Completed : Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas
:
  • Neurofibromatosis Type 1
  • Precancerous Condition

: 2002-02-14
:
  • Drug: Methotrexate Methotrexat

Completed : Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
: Cancer
: 2006-06-19
Completed : Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations
: Cancer
: 2014-04-24
:
  • Drug: Trametinib Trametinib is

Completed : PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma
:
  • Neoplasm of Uncertain Malignant Potential
  • Unspecified Childhood Solid Tumor, Protocol Specif
    : 2005-11-11
    : Biological: PEG-interferon alfa-2a
Completed : AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
:
  • Neurofibromatosis 1
  • Neurofibromatosis Type 1
  • NF 1
  • : 2011-05-27
    : Drug: AZD6244 AZD6244 orally every 12 hours on continuous daily schedule for cycles of 28 days until una
Completed : Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
: Neurofibromatosis
: 2012-08-22
: Drug: Gleevec Gleevec® will be dosed orally 440 mg/m^2/day (max 800 mg/day) for pediatric subjects
Completed : Neurofibromatosis Type 1 Patient Registry
: Neurofibromatosis Type 1
: 2011-08-02
Completed : Modifying Genes in Neurofibromatosis 1
: Neurofibromatosis 1
: 2012-05-29
: Other: No intervention No intervention
<<< Previous | Next >>>
Orthopedics Health
Orthopedics Health WebHealth Network Media
  • WebHealthNetwork
  • DiabetesHealthMatters
  • HeartandStrokeHealth
  • WomensHealthCareCommunity
  • AsthmaHealthCenter
  • CancerHealthCenter
  • MentalHealthHelpCenter
  • Skincarehealthcenter
  • DigestiveTractHealth
  • VaccineHealthCenter
  • PainHealthCenter
  • FightingAddictionCenter
  • ObesityHealthMatters
  • SeniorHealthcareMatters
  • BrainAndNerveCenter
  • PediatricsHealthCenter
  • RareDiseasesHealthCenter
  • Wealth Mason
  • Home Owners Circle
  • EasyInsuranceFinder
  • EduJumpStart
  • SaleSpider
  • ScoopCafe
  • SaleSpiderMedia
  • Viewpoint.World
  • TravelerBooked
  • TechNewsBytes
  • Contact Us
  • Advertising Privacy Policy

This site uses cookies for analytics and advertising. No personal information is collected.

© Orthopedics Health .

We use cookies to enhance your experience, analyze anonymized traffic, and deliver personalized content and ads. No personal information is collected. By using our website, you consent to our use of cookies and agree to our data practices as described in our Privacy Policy. To Reject, please change your browser settings.